Performance evaluation of the Cobas TaqMan MTB assay on respiratory specimens according to clinical application
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Eun, Park Jong | - |
dc.contributor.author | Huh Hee Jae | - |
dc.contributor.author | Koh Won-Jung | - |
dc.contributor.author | Song Dong Joon | - |
dc.contributor.author | Ki Chang-Seok | - |
dc.contributor.author | Lee Nam Yong | - |
dc.date.accessioned | 2023-11-14T08:47:03Z | - |
dc.date.available | 2023-11-14T08:47:03Z | - |
dc.date.created | 2023-07-07 | - |
dc.date.issued | 2017-11 | - |
dc.identifier.issn | 1201-9712 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/192388 | - |
dc.description.abstract | Objective: To evaluate the performance of the Cobas TaqMan MTB assay (Cobas assay) with respect to its clinical application.,Methods: This was a retrospective analysis of 1154 results from 1034 patients for whom mycobacterial cultures and the Cobas assay were performed simultaneously. Based on the patient medical records, two categories of clinical application were defined: (1) the diagnosis of patients with a high probability of pulmonary tuberculosis according to clinical and radiological features (n = 128), and (2) the exclusion of tuberculosis in clinically indeterminate patients (n = 1026). Standard culture was used as the reference method.,Results: The sensitivity of the Cobas assay for the detection of Mycobacterium tuberculosis was 70.4% (95% confidence interval (CI) 49.7-85.5%) for category 1, but only 25.0% (95% CI 4.5-64.4%) for category 2. The specificity was >= 95.0% for both categories. The positive predictive value was 79.2% (95% CI 57.3-92.1%) for category 1 and 33.3% (95% CI 6.0-75.9%) for category 2, while the negative predictive value was 92.3% (95% CI 85.0-96.4%) for category 1 and 99.4% (95% CI 98.7-99.8%) for category 2.,Conclusions: The results of this study indicate that Cobas assay results must be interpreted carefully according to the clinical purpose of the assay. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Performance evaluation of the Cobas TaqMan MTB assay on respiratory specimens according to clinical application | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Eun, Park Jong | - |
dc.identifier.doi | 10.1016/j.ijid.2017.08.014 | - |
dc.identifier.scopusid | 2-s2.0-85030152224 | - |
dc.identifier.wosid | 000414258000008 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, v.64, pp.42 - 46 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.volume | 64 | - |
dc.citation.startPage | 42 | - |
dc.citation.endPage | 46 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | MYCOBACTERIUM-TUBERCULOSIS COMPLEX | - |
dc.subject.keywordPlus | POLYMERASE-CHAIN-REACTION | - |
dc.subject.keywordPlus | PCR | - |
dc.subject.keywordAuthor | Mycobacterium tuberculosis | - |
dc.subject.keywordAuthor | Pulmonary tuberculosis | - |
dc.subject.keywordAuthor | Cobas TaqMan MTB assay | - |
dc.subject.keywordAuthor | Korea | - |
dc.identifier.url | https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1201971217302205?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1201971217302205%3Fshowall%3Dtrue&referrer= | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.